Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Biofactors. 2021 Sep;47(5):778-787. doi: 10.1002/biof.1761. Epub 2021 Jun 5.
Control rats were exposed to saline aerosol, two groups were exposed to paraquat (PQ), 27 (PQ-L) and 54 (PQ-H) mg/m aerosols and six groups were treated with carvacrol, 20 (C-L) and 80 (C-H) mg/kg/day, pioglitazone, 5 (Pio-L) and 10 (Pio-H) mg/kg/day, C-L+Pio-L and dexamethasone, 0.03 mg/kg/day, for 16 days after the end of exposure to PQ-H. Different variables were measured after the end of treatment period. Total and differential white blood cells counts, nitrite, malondialdehyde, interleukin (IL)-10, and interferon-gamma levels were significant increased, but thiol, superoxide dismutase, catalase, IL-17, and tumor necrosis factor alpha were decreased in the blood due to both doses of PQ (p < 0.05-p < 0.001). Most measured parameters were significantly improved in treated groups with both doses of carvacrol, pioglitazone, the combination of C-L+Pio-L and dexamethasone compared to PQ-H group (p < 0.05-p < 0.001). Treatment with C-L+Pio-L showed significantly higher effects compared to each one alone (p < 0.05-p < 0.001). Systemic oxidative stress and inflammation due to inhaled PQ were improved by carvacrol and pioglitazone. Higher effects of C-L+Pio-L than each one alone suggests carvacrol modulating PPAR-γ receptors.
对照组大鼠暴露于盐水气溶胶中,两组大鼠暴露于百草枯(PQ),27(PQ-L)和 54(PQ-H)mg/m 气溶胶中,六组大鼠分别用香芹酚、20(C-L)和 80(C-H)mg/kg/天、吡格列酮、5(Pio-L)和 10(Pio-H)mg/kg/天、C-L+Pio-L 和地塞米松,0.03mg/kg/天治疗,在暴露于 PQ-H 结束后 16 天。治疗期结束后测量了不同变量。由于 PQ 的两个剂量,血液中的总白细胞和分类白细胞计数、亚硝酸盐、丙二醛、白细胞介素(IL)-10 和干扰素-γ水平显著升高,但巯基、超氧化物歧化酶、过氧化氢酶、IL-17 和肿瘤坏死因子-α降低(p<0.05-p<0.001)。与 PQ-H 组相比,用香芹酚、吡格列酮、C-L+Pio-L 联合地塞米松治疗的两个剂量组的大多数测量参数均显著改善(p<0.05-p<0.001)。与单独使用 C-L 或 Pio-L 相比,C-L+Pio-L 治疗的效果明显更高(p<0.05-p<0.001)。香芹酚和吡格列酮改善了吸入 PQ 引起的全身氧化应激和炎症。C-L+Pio-L 的效果高于单独使用 C-L 或 Pio-L,提示香芹酚调节过氧化物酶体增殖物激活受体-γ(PPAR-γ)受体。